Protocol Ledger

NCT07010263 · Phase III · RECRUITING

A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Interventional Phase III clinical trial protocol NCT07010263 sponsored by Akeso in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-06-13 Enrollment: 560 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07010263
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)560 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07010263
Protocol FieldVerified Registry Value
NCT IdentifierNCT07010263
Consolidated Lead SponsorAkeso
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment560 participants (ESTIMATED)
Registered Start Date2025-06-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07010263
Hospital Research SiteLocationSite Profile
Beijing Cancer HospitalBeijing, ChinaOpen Hospital Dossier ->
The First Affiliated Hospital of Chongqing Medical UniversityChongqing, ChinaOpen Hospital Dossier ->
Fujian Cancer HospitalFuzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI